Other targets, such as Ataxia Telangiectasia Mutated (ATM), have been reported to upregulate PD-L1 expression via the JAK1, 2/STAT3 pathway, mediating the cisplatin-resistance in lung cancer cells [70]. This evidence concerns the gene STAT3 and lung cancer.